Inven2 AS
Development services for minimally invasive glaucoma surgery (MIGS) device
Inven2 AS has cancelled a competition for development services for a minimally invasive glaucoma surgery (MIGS) device, intended to lower intraocular pressure. The services, to be delivered in Oslo, involved optimizing stent design, prototyping, and in vitro testing, with an estimated development period of two years and a total contract value of up to 3 million NOK over 60 months. The cancellation was due to invalid offers, as the received bids either deviated from the tender documents or were submitted after the deadline.